Organization | Reade Rheumatology Research Institute

Reade Rheumatology Research Institute Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Amsterdam Netherlands

Organization Overview

First Clinical Trial

2007

NCT00462111

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Reade Rheumatology Research Institute | Sint Maartenskliniek

Active Ingredients

Drugs in Phase 4 Trials (8)

adalimumab (humira) (2 trials)

clarithromycin (biaxin) (1 trial)

doxycycline (vibramycin) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

indomethacin (indocin) (1 trial)

ropivacaine (naropin) (1 trial)

sodium chloride (1 trial)

tocilizumab (actemra) (1 trial)

Drugs in Phase 3 Trials (1)

rituximab (rituxan) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Borrelia Infections (Phase 4)

Lyme Disease (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 8
# of Trial APIs: 9